Title:
INHIBITOR OF CYCLIN-DEPENDENT KINASE
Document Type and Number:
Japanese Patent JP2021107396
Kind Code:
A
Abstract:
To provide novel compounds expressed by formula (I), (II), or (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof.SOLUTION: Provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK7, CDK12, or CDK13), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.SELECTED DRAWING: None
Inventors:
NATHANAEL S GRAY
ZHANG TINGHU
NICHOLAS PAUL KWIATKOWSKI
ZHANG TINGHU
NICHOLAS PAUL KWIATKOWSKI
Application Number:
JP2021054539A
Publication Date:
July 29, 2021
Filing Date:
March 29, 2021
Export Citation:
Assignee:
DANA FARBER CANCER INST INC
International Classes:
C07D487/04; A61K31/519; A61K31/53; A61P35/00; A61P35/02; A61P43/00
Domestic Patent References:
| JP2004517075A | 2004-06-10 | |||
| JP2002537300A | 2002-11-05 | |||
| JPH11514336A | 1999-12-07 | |||
| JP2004516326A | 2004-06-03 | |||
| JP2000515550A | 2000-11-21 | |||
| JP2015503625A | 2015-02-02 | |||
| JP2014526549A | 2014-10-06 |
Foreign References:
| WO2015006754A2 | 2015-01-15 |
Attorney, Agent or Firm:
Kiyoji Kuzuwa